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Post-treatment Lyme disease syndrome
Measurement
Function
S U M M A R Y
Objectives: The study objective is to demonstrate the clinical and research utility of an operationalized
deﬁnition of post-treatment Lyme disease syndrome (PTLDS), as proposed by the Infectious Diseases
Society of America.
Methods: Seventy-four patients with conﬁrmed erythema migrans and 14 controls were enrolled.
Patient-reported symptoms and health function (SF-36) were collected pre-treatment and at follow-up
visits over 6 months post-treatment.
Results: Eight (11%) patients met our operationalized deﬁnition of PTLDS, which included self-reported
symptoms of fatigue, widespread musculoskeletal pain or cognitive complaints, and functional impact as
measured by a T score of <45 on the composite SF-36. No controls met the functional impact criteria.
Forty-three (60% patients returned to their previous health status when measured at 6 months post-
treatment. Twenty (28%) patients had either residual symptoms or functional impact, but not both, and
did not meet criteria for PTLDS.
Conclusions: This operationalized deﬁnition of PTLDS allows for identiﬁcation of those patients who are
treated for early Lyme disease and have signiﬁcant post-treatment illness, as they have both residual
symptoms and impact on daily life functioning. With further reﬁnement and improvement of this
operationalized deﬁnition, the true incidence of PTLDS can be determined and future studies can be
designed to examine its pathophysiology and treatment.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Lyme disease is a worldwide emerging infectious disease with
increasing public health importance in North America and
countries with moderate climates in Eurasia.1 In North America,
Lyme disease is caused by infection with the spirochete bacterium
Borrelia burgdorferi and results in an early localized skin infection
called erythema migrans (EM). In approximately 50% of patients, B.
burgdorferi infection is associated with bloodstream dissemina-
tion.2,3 If untreated, the early skin infection resolves, but later
neurologic symptoms occur within weeks in approximately 15%,
and joint swelling and pain develop in approximately 60% of
patients within months of initial infection.4
Antibiotic treatment of early Lyme disease hastens the resolution
of skin disease and largely prevents later manifestations of cranial
neuritis, meningitis, carditis, and joint synovitis.5 However, 10–15%
of ideally treated patients develop post-treatment Lyme disease* Corresponding author. Tel.: +1 410 583 7124; fax: +1 410 583 7125.
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http://dx.doi.org/10.1016/j.ijid.2013.01.008syndrome (PTLDS), which is characterized by persistent or recurrent
symptoms of fatigue, musculoskeletal pain, and cognitive com-
plaints leading to functional decline.1,6 The Infectious Diseases
Society of America (IDSA) has proposed a research case deﬁnition of
PTLDS.7 As with criteria for other infection-associated, post-
treatment syndromes such as rheumatic fever, the criteria must
link the clinical phenotype with reliable markers of prior infection.8
However, there are currently no such reliable biomarkers or
serologic tests to deﬁne prior exposure to treated early infection
with B. burgdorferi, as prompt antibiotic treatment of seronegative
cases of early Lyme disease may prevent seroconversion, and the
majority of patients who do seroconvert acutely lose diagnostic
seroreactivity over the following year.9,10 The IDSA PTLDS case
deﬁnition includes a clinical syndrome of patient-reported symp-
toms that occurs in the context of documentation of a previously
treated, physician-diagnosed case of Lyme disease meeting the
Centers for Disease Control and Prevention (CDC) surveillance
criteria,11 and includes symptoms of such severity that they cause
signiﬁcant decline in physical or social functioning.7 There are
additional criteria to exclude patients with untreated tick-
borne infections or other illnesses with similar clinical features,ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Baseline demographics of early Lyme disease cases and controls
Cases (n = 71) Controls (n = 14)
Mean  SD (range) Mean  SD (range)
Age, years 49.83  15.36 (20–77) 51.21  12.81 (22–70)
Years of formal schooling 16.32  2.55 (11–21) 17.71  2.23 (14–21)
Income, US$ 139 852  107 494
(27 000–500 000)
165 000  75 609
(75 000–350 000)
n (%) n (%)
Sex
Female 34 (48%) 9 (64%)
Race
White 68 (96%) 14 (100%)
Black 1 (1%) 0 (0%)
Other 2 (3%) 0 (0%)
Highest degree attained
Less than high school 1 (1%) 0 (0%)
High school 7 (10%) 0 (0%)
Some college 13 (18%) 1 (7%)
College 21 (30%) 4 (29%)
Advanced degree 29 (41%) 9 (64%)
SD, standard deviation.
J.N. Aucott et al. / International Journal of Infectious Diseases 17 (2013) e443–e449e444such as preexisting ﬁbromyalgia, chronic fatigue syndrome, or
depression.
No studies have attempted to operationalize the IDSA case
deﬁnition of PTLDS, and the application of the IDSA case deﬁnition
has been variable across studies. Consequently, it is difﬁcult to
integrate the literature on PTLDS to glean true incidence and
prevalence rates, to further work towards understanding possible
biologic and psychological factors in the development of PTLDS,
and to design and test appropriate interventions. The creation of an
operationally-deﬁned ‘gold standard’ for the diagnosis of PTLDS is
essential to further this work. The primary aim of this study is to
propose a starting point from which a collaborative effort can begin
to clarify the deﬁnition of PTLDS in the community setting. We
propose the foundation of an operationalized approach to the
diagnosis of PTLDS and demonstrate its application in a cohort of
patients with early Lyme disease who were prospectively followed
for 6 months post-treatment.
2. Methods
Eligible patients included adults being evaluated for skin
lesions at an urgent care facility or primary care ofﬁce in a
suburban community of Baltimore, Maryland. Patients were
referred to and asked to participate in the study (approved by
the Johns Hopkins Medicine Institutional Review Board) by a
trained physician (JNA). Patients consented to study participation
and were screened for eligibility.
Eligible participants were required to have a clinician-
diagnosed EM, as well as evidence of systemic disease, which
commonly presents as dissemination of the primary EM or ﬂu-like
symptoms. This inclusion criterion was chosen to enrich the cohort
for the outcome of interest, which included biologic and clinical
evidence of PTLDS. While physician-documented EM alone gives
rise to a diagnosis of Lyme disease, we chose to enroll those
patients who had additional signs and symptoms of systemic
disease to allow us to capture a greater number of patients who
may be at higher risk of developing PTLDS.5 Exclusion criteria,
based upon the IDSA case deﬁnition of PTLDS,7 included prior Lyme
disease or any of the following preexisting conditions, as
determined by a screening history taken from the patient: chronic
fatigue syndrome, ﬁbromyalgia, depressive disorders, cancer, and/
or autoimmune conditions, as some of the symptoms associated
with these conditions (i.e., fatigue, pain, and cognitive complaints)
overlap with those of PTLDS.
The current study is part of a larger cohort study of Lyme
disease and PTLDS in which participants were treated with a 3-
week course of oral doxycycline and followed post-treatment for a
period of up to 2 years.6 The current study focused on the time
period from time of diagnosis of Lyme disease through 6 months
post-treatment, including visits immediately post-treatment
(approximately 3 weeks after the ﬁrst), 4 weeks post-treatment,
and 3 months post-treatment. During the initial visit, at time of
diagnosis, demographic information and medical history were
recorded. At all study visits, participants underwent a physical
exam, a clinical interview that included symptom reporting,
interval medical history and medication usage, and self-adminis-
tered the 36-item Short Form Health Survey, Version 2 (SF-36).
Controls were recruited by ﬂyer advertisement in the same
primary care facilities used to recruit Lyme cases. Controls were
matched to cases based on sex, age at time of enrollment ( 3
years), and the following comorbid conditions: endocrine illness
including diabetes and thyroid disease, migraine headaches, heart
disease, hypertension, and post-menopausal status. A total of 222
volunteers were screened for eligibility as controls. Of those, 138
were not eligible due to a preexisting condition that made them
ineligible for the study and 70 were eligible but did not match any ofthe Lyme disease case participants currently enrolled in the study.
Fourteen controls were eligible, matched to an enrolled case, and
were enrolled in the study. Controls were screened using the same
exclusion criteria as cases, which were conﬁrmed by review of their
medical records. Controls did not differ signiﬁcantly from cases in
demographic characteristics (see Table 1).
2.1. Symptom reporting
Self-reported symptoms were elicited from patients by trained
study staff from a list of 37 symptoms. At the ﬁrst visit, patients
were asked if they had or had not experienced each symptom
starting at the time of infection, which was indicated by (1) rash
development, or (2) new symptom onset preceding the rash. At
subsequent study visits, patients were instructed to indicate if each
symptom in the list was better, the same, worse, new, had
returned, or had remained absent since the previous study visit,
and to report any new symptom that was not on the list. Study staff
members administered the symptom questionnaire in a consistent
fashion, following written prompts, and were instructed not to
probe for speciﬁc symptoms, but instead read the entire list of
symptoms, as well as indicate if the patient experienced any
symptom that was not on the list. Reported symptoms did not need
to be present on the day of the study visit, only experienced during
the prior interval.5
To meet the IDSA PTLDS deﬁnition, patients had to have
experienced one of the following self-reported symptoms:
widespread musculoskeletal pain, fatigue, and/or cognitive com-
plaints. Our criteria for widespread musculoskeletal pain, vaguely
deﬁned in the IDSA deﬁnition, include a sum of the number of
times patients report a different anatomic site of pain on the
symptom survey. This includes joint pain (in any of 18 areas of the
body), muscle pain (in any of eight areas of the body), headache,
neck pain, and back pain. Patients were required to have at least
three areas of pain to meet criteria for reported musculoskeletal
pain. This is consistent with criteria for similar syndromes, such as
ﬁbromyalgia, which have historically been deﬁned by a threshold
number of tender points. Fatigue was measured through physi-
cian-elicited self-report and represents the patient’s endorsement
that fatigue is present since the start of the infection and the onset
of fatigue represents a change from his/her pre-infection status.
Cognitive complaints were deﬁned as the subjective experience of
any of the following: difﬁculty ﬁnding words, difﬁculty focusing or
concentrating, or memory impact. As stated previously, these
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merely have been experienced during the prior interval. As
symptoms of PTLDS have been noted to be intermittent, it was felt
to be a more sensitive indicator to include symptoms not present
on the actual day of the examination.5
2.2. Functional impact
The perceived impact of health status on life functioning was
assessed using the SF-36 at every study visit.12 This survey was
designed to capture eight health attributes (i.e., physical function-
ing, role physical, bodily pain, general health, vitality, social
functioning, role emotional, and mental health) and has been
shown to have high reliability and validity across a range of
populations.12 There is a standardized subscale score for each of the
eight health attributes with lower scores reﬂecting more negative
impact of health status on that area of life functioning and with a T of
50 reﬂecting the mean of the US general population. Using norm-
based scoring, all standardized scores are equated so that scores of
50 or above are better than the general population average and
scores below 50 are worse.12 In our sample, we found Cronbach’s a
of >0.85 for all subscales. We created a total mean score of all eight
subscales and a composite score of four subscales (role physical,
vitality, role emotional, and mental health; a mean of the
standardized score for each subscale) based upon our prior ﬁndings
suggesting that these sub-scores are particularly sensitive to the
functional impact in PTLDS.6We chose a cut-off T-score of <45, less
than 0.5 standard deviation (SD) below the normative mean, to
indicate a negative impact on life functioning. Although we
recognize that there will be non-clinical individuals in the general
population who will naturally be below this cut-off because of other
health problems, our goal is to maximize sensitivity at the expense of
speciﬁcity at this point in the development of the operationalized
deﬁnition. Figure 1 displays the IDSA deﬁnition versus our proposed
operationalized deﬁnition of PTLDS.Figure 1. IDSA proposed7 and authors’ propo3. Results
3.1. Cohort characteristics
Seventy-four patients with conﬁrmed early Lyme disease were
enrolled. Three individuals (4%) were lost to follow-up, however
they were not found to differ from the rest of the cohort on age,
education level, income level, gender, or race. The characteristics of
our study cohort (see Table 1) are similar to those previously
reported in the literature for patients with Lyme disease.13
Over the course of the study (between 1 and 6 months post
initial treatment of EM), seven patients were retreated. Three
patients were retreated at 3 months post-treatment with
intravenous ceftriaxone due to neuropathy veriﬁed by nerve
conduction studies. Three patients were retreated immediately
following the ﬁrst treatment with oral antibiotics due to a
persistent or enlarging EM rash. Two patients were retreated at
4 weeks post-treatment with oral antibiotics due to disabling
fatigue. One patient was retreated twice, once for fatigue at 4
weeks post-treatment and again for neuropathy at 3 months post-
treatment. At the time of retreatment, four of the seven patients
met both the symptom and functional impact criteria for PTLDS,
with a range of the SF-36 composite score between T = 21 and
T = 43. Of the seven retreated patients, three went on to meet our
criteria for PTLDS at the 6-month follow-up visit. These sequelae
and rates of retreatment are similar to those seen in other studies
of early Lyme disease.14
3.2. Symptom criteria
In our cohort of patients, nine met criteria for widespread
musculoskeletal pain, 13 met criteria for fatigue, and 17 met
criteria for cognitive complaints. Sixteen patients met criteria for
one of these three areas, seven met criteria for two areas, and three
patients met criteria for all three areas of the clinical symptomsed operationalized deﬁnition of PTLDS.
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symptom-positive’ in our analysis, having met at least one of the
three symptom requirements of the IDSA’s deﬁnition of PTLDS.
3.3. Functional impact
We conducted an analysis of variance (ANOVA) to determine
whether the three groups (PTLDS symptom-positive, PTLDS
symptom-negative, and controls) differed in the impact of life
functioning (total SF-36 score). The groups were found to differ
(F(2) = 4.84, p = 0.01), with post-hoc analyses demonstrating that
the PTLDS symptom-positive group differed signiﬁcantly from the
PTLDS symptom-negative group (p = 0.004) and controls
(p = 0.03); however the PTLDS symptom-negative group did not
differ signiﬁcantly from controls (p = 0.93). Figure 2a shows the
mean total scores for each of these three groups. Using the
standardized SF-36 total score of a T <45 as the deﬁnition of
functional impact, ﬁve participants were identiﬁed as PTLDS-
positive.
To determine the impact on life functioning speciﬁc to
individuals with PTLDS, we created a composite score based upon
our previous research using the SF-36 in an early Lyme cohort.15 An
ANOVA revealed that the three groups differed on this composite
score (F(2) = 7.46, p = 0.001), with post-hoc analyses demonstrat-
ing that the PTLDS symptom-positive group differed signiﬁcantly
from the PTLDS symptom-negative group (p < 0.001) and the
control group (p = 0.01); however the PTLDS symptom-negativeFigure 2. Functional performance on SF-36 (Total mean t-score, a, and 4 Subscale com
summary score, d, of participants with and without PTLDS symptoms and control partgroup did not differ signiﬁcantly from the control group (p = 0.83).
Using this composite score, there were eight individuals who were
PTLDS symptom-positive who were below the cut-off of T = 45, and
there was a clearer division between patients with symptoms who
endorsed impact on life functioning and those who did not (see
Figure 2b). Using these criteria, twenty (28%) patients had either
residual symptoms or functional impact, but not both, and did not
meet criteria for PTLDS. Forty-three (60%) patients returned to
their pre-Lyme health status when measured at six months post-
treatment. When compared to using the physical component score
and mental component score provided by the SF-36, our composite
score performed better in distinguishing between the three patient
populations (see Figures 2c and 2d); no signiﬁcant differences
between the three groups were seen in either the physical
component score (p = 0.1381) or the mental component score
(p = 0.1766). There was an even distribution of those individuals
who were retreated with a second course of antibiotics among all
three outcome groups.
4. Discussion
Persistent musculoskeletal pain, neurologic symptoms, and
fatigue that can follow treatment of early Lyme disease have been
well documented in the early literature.15–18 Not until a decade
later was a proposed case deﬁnition for PTLDS included in the IDSA
guidelines. Although the IDSA provided a starting point for deﬁning
PTLDS,7,18 the stated criteria leave much open to interpretation.posite t-score, b), Physical Component summary score, c, and Mental Component
icipants at 6 months post-treatment.
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functional impact, clinicians and researchers are left to decide on
their own. It is unknown how often or in what manner these
criteria are applied.
Across studies, researchers have consistently used the criteria
that individuals must have persistence of self-reported symptoms
such as pain and fatigue, but these symptoms have often been
reported as present or absent, or as part of an aggregate outcome of
complete versus partial response to therapy, as in prior antibiotic
treatment trials.14,19–23 Attempts to measure cognitive complaints
have not demonstrated large deﬁcits in PTLDS.24 No data from
prospective studies of early Lyme disease have used validated
measures of fatigue, and only a single study in Europe has included
non-Lyme infected controls.25 Because of the limitations of
previous studies, it remains unknown whether the severity of
fatigue in PTLDS is greater than that of baseline levels found in
otherwise healthy populations.7 Such variability of the approaches
to capture these symptoms has led to a literature base that is
difﬁcult to reconcile.
Consideration of the ‘functional impact’ component of the IDSA
case deﬁnition reﬂects even greater variability across studies.
Studies prior to the establishment of the IDSA criteria,24 and even
some studies since,23,26 have not included the functional impact
criteria in order to classify subjects in the PTLDS group. Even when
this criterion has been applied as part of the study inclusion
criteria, the deﬁnition has varied, including deﬁning ‘functional
impact’ as ‘symptoms were severe enough to interfere with
activities of daily living’,27 to using standardized assessment tools
to capture the functional impact of the symptoms.6 Such variability
in deﬁning individuals who meet the criteria for PTLDS leads to
obstacles in integrating ﬁndings across studies.
Given these challenges, we set out to begin the development of
an operationalized deﬁnition of PTLDS by offering a two-step
approach to PTLDS diagnosis that could be used to evaluate
persistent symptoms after proper treatment of Lyme disease. The
ﬁrst step focuses on patient-reported symptoms of pain, fatigue,
and/or cognitive complaints. The presence of the symptoms
indicates that the patient endorsed that the symptom began after
exposure to and treatment for Lyme disease. As consistent with the
IDSA deﬁnition, we accepted that self-report of the persistence or
new appearance of these symptoms is sufﬁcient to meet criteria
without the need to quantify the magnitude of the symptoms.
Further research should investigate if the symptom criteria need to
include a measurement of severity of the symptom using
structured symptom surveys to set a threshold level. Once
symptoms are quantiﬁed they should be examined for their
speciﬁc impact on patient function. This will allow for further
reﬁnement of the IDSA criteria and may also point out the need for
inclusion of other symptoms that contribute to a decline in
function. For example, the syndromes that are closely related to
PTLDS such as ﬁbromyalgia16 and chronic fatigue syndrome,28
suggest that un-refreshing sleep, post-exertional malaise, the
presence of tender points, and neurologic symptoms such as
allodynia may be important.29–31
Additionally, future research should focus on clearly deﬁning
the constructs of fatigue, as it is recognized in the scientiﬁc
literature that there are different types of fatigue (physical fatigue
versus mental fatigue) and that the severity, duration, and
frequency of fatigue may differ across patients. Finally, there
needs to be attention to the experience of cognitive impact as
reported by patients versus the objective evidence of cognitive
deﬁcits as shown on neuropsychological testing. Although an
individual may feel less cognitive efﬁcient, that does not mean that
a primary cognitive impairment is present given that there are
many factors that can distract our cognitive resources, such as pain,
fatigue, and emotional distress.The second step in the diagnosis of PTLDS focuses on the
functional impact of the symptoms. We employed a well-validated
instrument to measure the patient’s perceived impact of health
status on his/her daily life functioning to avoid the pitfalls inherent
in unvalidated methods to capture the patient’s perception of their
health-related function. Although the SF-36 still relies upon
patient self-report and cannot directly compare current function
to the patient’s previous level of function, it allows for a more
precise capture of the quality and magnitude of symptom impact
on functioning and has been recommended for use in other
symptom-based illnesses such as chronic fatigue syndrome.29
With such a structured assessment approach, it is possible for
researchers to compare individuals based upon the degree of
impact as well as whether there are differences between
individuals by type of impact. For example, in previously healthy
individuals, SF-36 scores below the mean (T = 50) have been used
to deﬁne signiﬁcant levels of health-related vitality.32 In addition,
the SF-36 affords the opportunity to more closely analyze the
differences between individuals who have persistent symptoms
and endorse ‘signiﬁcant’ impact on functioning versus those
individuals who have persistent symptoms, but continue to report
adequate functioning.
We chose more than 0.5 SD below the normative mean (T = 45)
as a preliminary cut-off point for identifying individuals who rated
the impact of their health status (i.e. symptoms) on life functioning
as ‘less than average’. Obviously, in the general population, there
are individuals who fall below this threshold on their life
functioning, and the SF-36 captures this normal distribution.
The SF-36 allows for operationalizing the perception of the impact.
Using the SF-36, we were able to show that we could clearly
identify a subgroup of individuals who meet the symptom criteria
for PTLDS and fall below this cut-off point, indicating negative
functional impact. We recognize that this cut-off of more than 0.5
SD below the normative mean will allow for more false-positives
among Lyme disease patients; however, one could argue that even
if these individuals are being incorrectly classiﬁed as PTLDS
patients, they could still beneﬁt from behavioral interventions to
address their symptoms and to increase their life functioning. In
our study, no healthy controls fell below our cut-off. Future
research will have to consider in the selection of control subjects
that there may be individuals in the general population with
undiagnosed medical problems who have symptoms leading to
functional impact meeting this criterion. In addition, our pattern of
results suggests that in our study population of previously healthy
individuals, PTLDS outcomes will have some overlap with those in
the general population. Future studies will need to examine other
risk factors for more severe outcomes in PTLDS, including
preexisting conditions such as depression and the impact of
delays in initial diagnosis and treatment. In the current study,
using a composite score of the SF-36 sub-scores, we identiﬁed a
subgroup of individuals who have PTLDS symptoms and impact on
life functioning. Using this composite score versus the general
score, there is a clearer division between patients with symptoms
who endorse impact on life functioning and those who do not. This
subgroup is 11% of the entire sample and 31% of the subsample
meeting the symptom-only criteria of PTLDS (see Figure 3). It is
unclear how the group with persistent symptoms who endorse
normal functioning is distinguished from those who endorse both
symptoms and reduced functioning. Future research should
address the nature, magnitude, and signiﬁcance of persistent
symptoms among those not reporting functional impact, as well as
to delineate which factors are most negatively affecting the life
functioning of those with PTLDS. Additionally, the validity and
reliability of our SF-36 composite score should be conﬁrmed to
determine if it truly captures the core functional domains
impacted by PTLDS.
Figure 3. Outcome status for participants treated for early Lyme disease measured
at 6 months post-treatment.
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regardless of the etiology of their symptoms and thus warrant
appropriate intervention. Given a lack of consensus in the
literature for identifying and treating possible physiologic causes
for persisting symptoms, clinical care must not neglect the need for
targeting symptom management. There is solid literature on
behavioral pain management and the effectiveness for improving
life functioning.33–35 There are cognitive rehabilitation interven-
tions that can assist individuals in improving their life functioning
regardless of the cause of the cognitive symptoms.36,37 And there
are behavioral interventions for fatigue management across
populations that facilitate the individual maximizing their
participation in life activities.38–40 All of these interventions are
currently available, and so one goal for clinicians should be to
identify those individuals who are suffering with PTLDS and refer
them for appropriate interventions based upon individual symp-
tom presentation.
From a research stand-point, the operationalization of the
PTLDS deﬁnition should provide a framework for identifying those
individuals in future studies on Lyme disease. This is our initial
attempt to highlight some of the challenges for developing a
deﬁnition that is both sensitive and speciﬁc for PTLDS. For instance,
the current IDSA proposed deﬁnition requires symptom onset
within the ﬁrst 6 months after diagnosis and treatment of Lyme
disease and persistence of continuous or relapsing symptoms for at
least 6 months to meet the deﬁnition of PTLDS. In our cohort
several patients met the case deﬁnition of PTLDS at earlier time
points before their 6 month visits and were retreated with
antibiotics for evidence of persistent rash, neurologic signs, or
disabling symptoms. Because of the small numbers of patients
involved in our study it is unknown what impact retreatment has
on the clinical course of early Lyme disease, although other experts
have endorsed this clinical practice.41,42 The impact of antibiotic
retreatment and the risk of developing future PTLDS has not been
studied. The sensitivity of the proposed IDSA deﬁnition may also be
diminished by missing cases of PTLDS with onset of symptoms at
>6 months. In addition, because the symptoms of PTLDS in ideally
diagnosed and treated early Lyme disease are likely to be mild,5 it is
not surprising that there will be overlap with the general
background levels of common symptoms such as fatigue and
pain, as well as with health functioning of the general population.
With a consistent approach across studies, ﬁndings can more
easily be compared and the true incidence of PTLDS can be
determined. Additionally, incorporating quantitative and repro-
ducible measures of symptoms (severity and course) and their
impact on life functioning provides a stronger foundation for
assessing the overall efﬁcacy of potential new pharmacologic andnon-pharmacologic treatment modalities for early and late Lyme
disease. Most recent studies on the treatment of Lyme disease have
focused on resolution of physical ﬁndings, such as the rash of early
Lyme disease or the joint swelling of late Lyme disease, as objective
parameters of treatment success. We suggest that outcome
variables also include patient-reported symptoms and functional
outcomes as part of the complete picture of treatment success. We
recognize that the proposed framework is an initial step that will
likely need further reﬁnement. However, a uniform approach
provides a starting point for the ﬁeld in the identiﬁcation of
individuals with PTLDS to address questions about reasons for
symptom persistence and identiﬁcation of potential interventions.
Our goal with this study was to provide a useful framework that
research and clinical communities could use to uniformly identify
individuals with PTLDS. The international scientiﬁc community
can and will continue to investigate the competing hypothesis
regarding the pathophysiological underpinnings of the persistence
of illness in the subgroup of individuals exposed to and treated for
Lyme disease.43–45 The development of more sophisticated and
sensitive biomarkers for B. burgdorferi, as well as the host immune
response, will lay the groundwork to develop future chemothera-
peutic approaches to PTLDS. Future biomarkers will be critical in
understanding what role infection and autoimmunity play in the
genesis of the patient’s symptoms. Until then, the question of what
role antibiotic or non-antibiotic therapy should play in the
treatment of PTLDS will remain the subject of debate.
The present challenges are to move toward a more uniform and
comprehensive evaluation and follow-up of patients after initial
antibiotic treatment of Lyme disease, including the use of
quantitative measures of patient reported symptoms and close
observation of patients for issues that may require early
retreatment after initial therapy. Physician-observed, objective
ﬁndings, such as the development of meningitis, cranial nerve
palsy, or radiculopathy, represent one well agreed upon indication
for retreatment with antibiotics.7 In addition, retreatment for early
persistent or recurrent patient-reported symptoms in the initial
weeks or months after completion of initial antibiotic therapy
remains an area that is hinted at in the literature but not
speciﬁcally addressed in the current literature.41,42 At the same
time, it is equally important to investigate the role of psychological
variables, such as coping patterns, the presence of pre-Lyme
psychopathology, and the possible vulnerabilities that put an
individual at risk for developing chronic symptoms. Or alterna-
tively, there should be consideration of the adaptive coping skills
that serve to protect individuals from the full impact of persistent
symptoms on their emotional and physiologic functioning. As this
work goes forward, it is critical that the clinical community has
valid and reliable ways to identify individuals who are in need of
further evaluation and treatment. That is good medical care.
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